LIVER Publication-derived

Heart-Liver Assembloid for Cardio-Hepatic Drug Interaction

Source Skardal et al. · Wake Forest Institute for Regenerative Medicine, Winston-Salem, USA · 10.1038/s41598-017-08879-x

👤 Skardal A, Murphy SV, Devarasetty M, Bhatt S, Bhatt DL, Bhatt AB, Bhatt P, Bhatt K, Atala A ⏱ 10080 min 🧫 iPSC-Derived (Human iPSC-CMs + Primary Hepatocytes)

Abstract

Skardal et al. developed a microfluidically linked heart-liver assembloid system demonstrating hepatic metabolism-dependent cardiotoxicity. The liver module converts pro-drugs to active metabolites that affect the cardiac module, revealing drug interactions invisible in single-organ culture and supporting systems-level pharmacology assessment.

Cell source

iPSC-Derived (Human iPSC-CMs + Primary Hepatocytes)

Application

Multi-Organ Drug Interaction

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Skardal et al.. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?

Use this protocol in your therapeutic or diagnostic pipeline.

Request Commercial Licence